Leramistat is under clinical development by Istesso and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Leramistat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Leramistat overview

MBS-2320 is under development for the treatment of rheumatoid arthritis, ulcerative colitis, multiple myeloma and autoimmune disorders. It is administered through oral route. It is a new molecular entity.

Istesso overview

Istesso, a subsidiary of IP Group Plc, is a pharmaceutical company that offers drug development services. The company provides sources for late-stage discovery projects from conducting early proof-of-principle clinical studies, and academic institutions, and provides out-licensing services. It develops novel therapeutic agents for treating chronic inflammatory and autoimmune disorders. Istesso offers its project development services through outsourcing the early development work to contract research organizations and research institutions. The company caters its services to the pharmaceutical and biotechnology industry. It serves research institutions and healthcare professionals. Istessois headquartered in London, England, the UK.

For a complete picture of Leramistat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.